Opportunities
Search

The National Science Foundation (NSF) and the National Institutes of Health (NIH) are interested in proposals that will propel our understanding of the biomedical research enterprise by drawing from the scientific expertise of the science of science policy research community. NSF promotes the progress of science by maintaining the general health of research and education across all fields of science and engineering. The Social, Behavioral and Economic Sciences (SBE) Directorate within NSF supports basic research on people and society. The SBE sciences focus on human behavior and social organizations; how social, economic, political, cultural and environmental forces affect the lives of people from birth to old age; and how people in turn shape those forces. SBE's Science of Science: Discovery, Communication and Impact Program (SoS:DCI) supports research designed to advance the scientific basis of science and innovation policy. The NIH is the U.S. federal agency charged with supporting biomedical research in the U.S.The National Institute of General Medical Sciences (NIGMS) within the NIH supports basic biomedical research that increases understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment and prevention. Both NSF and NIH believe that there are opportunities and needs for building and supporting research projects with a focus on the scientific research enterprise. The two agencies also recognize that when programmatic goals are compatible, coordinated management and funding of a research program can have a positive synerg...

The NSF CISE Directorate supports research and education projects that develop new knowledge in all aspects of computing, communications, and information science and engineering through the following Future Computing Research (Future CoRe) programs: Algorithmic Foundations (AF) program; Communications and Information Foundations (CIF) program; Computer Systems Research (CSR) program; Computing Education Research (CER) program; Cyber-Physical System Foundations and Connected Communities (CPS) program; Foundations of Emerging Technologies (FET) program; Human-Centered Computing (HCC) program; Information Integration and Informatics (III) program; Networking Technology and Systems (NeTS) program; Robust Intelligence (RI) program;and Software and Hardware Foundations (SHF) program; The CISE Future Computing Research program anticipates a portfolio of awards with a range of budgets and durations, including projects of smaller scope. Project durations and budgets must be commensurate with the scope of the proposed work up to the maximum limit of $1,000,000 with a duration up to 4 years. Typical projects are approximately $150,000 to $250,000 per year and are 3 to 4 years in duration. Projects are discouraged from exceeding $300,000 in any single year. Estimated program budget, number of awards, and average award size/duration are subject to the availability of funds.

Summary: The fiscal year 2026 (FY26) Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) supports promising research that accelerates drug discovery and therapeutic development for hearing restoration after military-relevant auditory system injury. The FRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 HRRP Focus Areas. The FRA cannot be used to support clinical trials, tinnitus research or vestibular research.Distinctive Features:• The FRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels.• Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI.• Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel.• Programmatic review criteria include adherence to the intent of the FRA, contribution to the HRRP portfolio, relative impact, and relevance to military health.

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the FY26 VRP Focus Areas. The MCRA may not be used to support preclinical research or clinical trials. Distinctive Features: ·        Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program), who will conduct the proposed research under mentorship of the PI, with support from supporting personnel as appropriate. ·        The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA.  ·        Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact and Personnel. ·        Programmatic review criteria include adherence to the intent of the MCRA, contribution to program portfolio, relative impact and relevance to military health. ·        Applicants must submit documentation of Institutional Review Board (IRB)/Ethics Committee (EC) approval or exemption by January 1, 2027, in order for the MCRA application to be considered for funding.  https://cd...

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy – Leadership Award (NFRALA) supports visionary, established neurofibromatosis (NF) investigators with documented history of neurofibromatosis funding, publications, strong mentorship and commitment to leadership to serve as Director and Deputy Director of the Neurofibromatosis Research Academy. The Academy Director and Deputy Director will execute a multi-institutional, interactive, virtual research academy that consists of scholars, who are early-career investigators, and their career guides, who serve as the scholars’ primary mentors.Distinctive Features:• Academy Director: Established NF investigators at or above the level of Associate Professor, or equivalent, at the full application submission deadline.• Academy Deputy Director: Investigators at or above the level of Associate Professor, or equivalent, at the full application deadline and affiliated with a different institution than the Academy Director.• Pilot Research Project: The Academy Director and Deputy Director will conduct one or more pilot research projects in collaboration with the academy scholars. Preliminary and/or published data relevant to NF and the proposed research project are encouraged but not required.

This funding partnership between the National Science Foundation (NSF) and the National Endowment for the Humanities (NEH) supports projects to develop and advance knowledge concerning dynamic language infrastructure in the context of endangered human languages — languages that are both understudied and at risk of falling out of use. Made urgent by the imminent loss of roughly half of the approximately 7,000 currently used languages, this effort aims to exploit advances in human-language technology to build computational infrastructure for endangered language research. The program supports projects that contribute to data management and archiving, and to the development of the next generation of researchers. Funding can support fieldwork and other activities relevant to the digital recording, documentation and analysis, and archiving of endangered language data, including the preparation of lexicons, grammars, text samples, and databases. Funding is available in the form of one- to three-year senior research grants and conference proposals. Fellowship support is available through a separate funding opportunity administered by NEH. Note: a conference proposal should generally be submitted at least a year in advance of the scheduled date of the conference. For additional information about creating and submitting conference proposals, please refer to PAPPG Chapter II. E.9.

The Probability Program supports research on the theory and applications of probability. Subfields include discrete probability, stochastic processes, limit theory, interacting particle systems, stochastic differential and partial differential equations, and Markov processes. Research in probability which involves applications to other areas of science and engineering is especially encouraged. Conferences Principal Investigators should carefully read the program solicitation "Conferences and Workshops in the Mathematical Sciences" (link below) to obtain important information regarding the substance of proposals for conferences, workshops, summer/winter schools, and similar activities. Conference and workshop proposals should be submitted eight months before the requested start date.

To support activities that develop, expand, strengthen, or sustain NIST partnership programs and/or support the conduct of research or a recipient's portion of collaborative research in a variety of areas including, but not limited to: Metrology; Standards; Nanotechnology; Artificial Intelligence; Advanced Communications; Advanced Manufacturing; Promotion of U.S. innovation and industrial competitiveness; Measurements in Sciences; Neutron Research; and enhancing coordination of the U.S. Standards System with government and private sector organizations.

Summary: The fiscal year 2026 (FY26) Reconstructive Transplant Research Program (RTRP) Concept Award supports the exploration of highly innovative new concepts or untested theories that address an important problem relevant to reconstructive transplantation. The Concept Award does not support clinical trials. Distinctive Features: ·        Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. ·        Relevance: Projects should address at least one of the FY26 RTRP Focus Areas. ·        Preliminary Data: Presentation of preliminary data is not allowed; however, applications should demonstrate the ability to achieve interpretable results. A rationale for the proposed work must be provided. ·        Early-Career Investigators: Early-career investigators are encouraged to apply. Investigators at or above the level of postdoctoral fellow are eligible to apply.

NTIA is soliciting applications for the Native Entities Grant Program (“Program”), authorized by the Infrastructure Investment and Jobs Act of 2021, Division F, Title III, Public Law 117-58, 135 Stat. 429, 1209 (November 15, 2021) (codified at 47 U.S.C. §1701, 1721, et seq.) (the “Digital Equity Act of 2021” or “Act”). The Act authorizes two programs that set aside funds for Indian Tribes, Alaska Native entities, and Native Hawaiian organizations (collectively “Native Entities”): the “State Digital Equity Capacity Grant Program” and the “Digital Equity Competitive Grant Program.” To reduce administrative burden and cost, NTIA is releasing the funds for both programs through a single application process.

NTIA is soliciting applications for funds remaining under the Tribal Broadband Connectivity Program (TBCP), authorized by the Consolidated Appropriations Act, 2021, Division N, Title IX, Section 905(c), Public Law 116-260, 134 Stat. 1182 (Dec. 27, 2020) (Act), as amended by the Infrastructure Investment and Jobs Act, Division F, Title II, Section 60201, Public Law 117-58, 135 Stat. 429 (Nov. 15, 2021) (IIJA) (codified at 47 U.S.C. §1705). TBCP provides funding for grants to Eligible Entities to expand access to and adoption of: (i) broadband service on Tribal Land; or (ii) programs that promote remote learning, telework, or telehealth resources.

The Division of Mathematical Sciences (DMS)in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF)and the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH)plan to support fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. Both agencies recognize the need to promote research at the interface between mathematical and life sciences. This program is designed to encourage new collaborations, as well as to support innovative activities by existing teams. The joint DMS/NIGMS initiative offers two submission tracks: Track 1 - for projects with a total budget of up to $600,000 for an award duration of 3 years, and Track 2 - for projects with a total budget of up to $1,200,000 for an award duration of 3-4 years.

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Establi...

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed.

The Combinatorics program supports research on discrete structures and includes algebraic, enumerative, existential, extremal, geometric, and probabilistic combinatorics, including graph theory. Conferences Principal Investigators should carefully read the program solicitation "Conferences and Workshops in the Mathematical Sciences" (link below) to obtain important information regarding the substance of proposals for conferences, workshops, summer/winter schools, and similar activities. Conference proposals must be submitted at least six months in advance of the conference, and in the same fiscal year (which begins October 1) if possible.

The program in Foundations supports research in mathematical logic and the foundations of mathematics, including proof theory, recursion theory, model theory, set theory, and infinitary combinatorics. Conferences Principal Investigators should carefully read the program solicitation "Conferences and Workshops in the Mathematical Sciences" (link below) to obtain important information regarding the substance of proposals for conferences, workshops, summer/winter schools, and similar activities. Conference and workshop proposals should be submitted eight months before the requested start date.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date.Supports three funding levels, each offered with and without a Planning Phase:Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants.Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants.Funding Level 3: Supports phase 3 clinical trials or non-phased trials with more than 300 participants.Funding D...

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Platform Clinical Translation Award supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two congressionally directed FY26 PRMRP topic areas. The platform product in development should address one of the FY26 PRMRP portfolio-specific strategic goals and address the health care needs of military Service Members, Veterans and their Families.Distinctive Features:Allows for multiple Principal Investigators (PIs). The proposed experiments may represent a single project led by a single PI, or it may consist of partnerships between principal investigators that will occur synergistically to advance a platform product. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. Up to two additional PIs can be identified as Partnering PIs. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).Requires a PI-convened external advisory board with patient advocate participation. The patient advocate must be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the applicant-selected congressionally directed FY26 PRMRP topic areas.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $30M to fund approximately two Platform Clinical Transl...

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy – Scholar Award (NFRA-SA) supports early-career independent investigators (Scholars) joining the Neurofibromatosis Research Academy to pursue a neurofibromatosis project that may include basic, translational, and/or clinical research. The proposed research should address at least one of the FY26 NFRP Areas of Emphasis, under the leadership of the NFRA Director and Deputy Director. The overarching goal of the NFRA is to conduct innovative and impactful research in the field of neurofibromatosis disorders while developing successful, highly productive NF researchers in a collaborative research and career development environment.Distinctive Features:• Scholar: The Scholar, named as the Principal Investigator, must be less than 10 years of completion of their terminal degree by the time of the application deadline (excluding time spent in residency, clinical training, or on family medical leave).• Career Guide: This award mechanism requires each Scholar to designate a Career Guide for guidance. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, the application must identify a secondary Career Guide at the Scholar’s institution.

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Investigator-Initiated Research Award (IIRA) supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.Distinctive Features: This award mechanism offers two funding levels based on participation in two optional features:• Open Science Initiative: Catalyzes research for neurofibromatosis through early access to data and data sharing within the neurofibromatosis community.• Optional Qualified Collaborator: Encourages collaborative research between basic scientists and clinical researchers, and between academic and biotechnology scientists.The funding levels are defined as follows:• Level 1: Applications without an optional feature.• Level 2: Applications including one of the optional features.

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in neurofibromatosis (NF) research. Studies supported by this award mechanism should lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.Distinctive Features:• Innovation: The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, examine existing problems from novel perspectives, or exhibit other highly creative qualities.• Preliminary Data: Preliminary and/or published data is encouraged but not required.

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Synergistic Idea Award (SIA) supports new ideas that represent synergistic approaches to neurofibromatosis (NF) research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in NF research. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.Distinctive Features:• Partnering Principal Investigators: One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. An additional one or two PI(s) will be identified as a Partnering PI. Each partner will be recognized as a PI, submit a separate application (even if the partners are at the same organization), and receive an individual award.

Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Care Award (TrCA) supports clinical research or clinical trials evaluating interventions, innovations, and solutions in critical areas for dementia care for individuals with Alzheimer’s disease and Alzheimer’s disease related dementia (AD/ADRD) and their care partner(s).Distinctive Features:Clinical research and clinical trials are allowed; however, clinical trials solely testing or evaluating pharmacological interventions do not meet the intent of this funding opportunity.Studies utilizing animal models do not meet the intent of the mechanism and are not allowed.Preliminary data are required.Community collaboration is required for research prospectively enrolling human subjects.The AZRP encourages studies to leverage existing cohorts/datasets. Cohorts consisting of individuals 65 years or younger are also encouraged.Career Initiation or Transition (CIT) Partnership Option: The TrCA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet the CIT Partnership Option eligibility requirements at the time of application submission.

Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Diagnosis Award (TrDA) supports non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and accurate prognosis.Distinctive Features:Clinical research is allowed, however clinical trials and animal research are prohibited. Preliminary data are required.Community collaboration is required for studies prospectively enrolling human subjects.Study Population: The AZRP encourages studies to leverage existing cohorts/datasets. Cohorts consisting of individuals 65 years or younger are also encouraged.Career Initiation or Transition (CIT) Partnership Option: The TrDA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet the CIT Partnership Option eligibility requirements at the time of application submission.

Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s disease and/or Alzheimer's disease related dementias (AD/ADRD).Distinctive Features:• Applications must address at least one of the following focus areas: ○ Risk Factor Knowledge: Research that advances understanding, identification, and/or validation of risk and/or protective factors, with research outcomes/products focused on accelerating solutions. Projects may include, but are not limited to, research on environmental, epigenetic, genetic, lifestyle, occupational, or other risks not listed here. ○ Risk Reduction Solutions: Research that describes methods, technologies, and strategies that contribute to reducing risk and preventing AD/ADRD.• Clinical research is allowed, however clinical trials and animal research are prohibited.• Preliminary data are required.• Community collaboration is required for research prospectively enrolling human subjects.• Career Initiation or Transition (CIT) Partnership Option: The TrRA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet